ifosfamide has been researched along with su 11248 in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I | 1 |
den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J | 1 |
Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
Inatsu, H; Kitamura, K; Nakashima, K | 1 |
2 review(s) available for ifosfamide and su 11248
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sarcoma; Sunitinib | 2007 |
1 trial(s) available for ifosfamide and su 11248
Article | Year |
---|---|
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Pyrroles; Sunitinib | 2010 |
3 other study(ies) available for ifosfamide and su 11248
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |